These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 29193038)
1. Emerging Clinical Importance of Hepatic Organic Cation Transporter 1 (OCT1) in Drug Pharmacokinetics, Dynamics, Pharmacogenetic Variability, and Drug Interactions. Zamek-Gliszczynski MJ; Giacomini KM; Zhang L Clin Pharmacol Ther; 2018 May; 103(5):758-760. PubMed ID: 29193038 [TBL] [Abstract][Full Text] [Related]
2. Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics. Shu Y; Brown C; Castro RA; Shi RJ; Lin ET; Owen RP; Sheardown SA; Yue L; Burchard EG; Brett CM; Giacomini KM Clin Pharmacol Ther; 2008 Feb; 83(2):273-80. PubMed ID: 17609683 [TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of Organic Cation Transporter 1 (OCT1) Substrates in Oct1/2 Knockout Mice and Species Difference in Hepatic OCT1-Mediated Uptake. Morse BL; Kolur A; Hudson LR; Hogan AT; Chen LH; Brackman RM; Sawada GA; Fallon JK; Smith PC; Hillgren KM Drug Metab Dispos; 2020 Feb; 48(2):93-105. PubMed ID: 31771949 [TBL] [Abstract][Full Text] [Related]
4. Ablation of both organic cation transporter (OCT)1 and OCT2 alters metformin pharmacokinetics but has no effect on tissue drug exposure and pharmacodynamics. Higgins JW; Bedwell DW; Zamek-Gliszczynski MJ Drug Metab Dispos; 2012 Jun; 40(6):1170-7. PubMed ID: 22407892 [TBL] [Abstract][Full Text] [Related]
5. Increased expression of hepatic organic cation transporter 1 and hepatic distribution of metformin in high-fat diet-induced obese mice. Jang EH; Kim HK; Park CS; Kang JH Drug Metab Pharmacokinet; 2010; 25(4):392-7. PubMed ID: 20814161 [TBL] [Abstract][Full Text] [Related]
6. Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver. Nies AT; Koepsell H; Winter S; Burk O; Klein K; Kerb R; Zanger UM; Keppler D; Schwab M; Schaeffeler E Hepatology; 2009 Oct; 50(4):1227-40. PubMed ID: 19591196 [TBL] [Abstract][Full Text] [Related]
7. The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin. Tzvetkov MV; Vormfelde SV; Balen D; Meineke I; Schmidt T; Sehrt D; Sabolić I; Koepsell H; Brockmöller J Clin Pharmacol Ther; 2009 Sep; 86(3):299-306. PubMed ID: 19536068 [TBL] [Abstract][Full Text] [Related]
8. Co-administration of nuciferine reduces the concentration of metformin in liver via differential inhibition of hepatic drug transporter OCT1 and MATE1. Li L; Lei H; Wang W; Du W; Yuan J; Tu M; Zhou H; Zeng S; Jiang H Biopharm Drug Dispos; 2018 Nov; 39(9):411-419. PubMed ID: 30294927 [TBL] [Abstract][Full Text] [Related]
9. A drug-drug interaction study to evaluate the impact of peficitinib on OCT1- and MATE1-mediated transport of metformin in healthy volunteers. Shibata M; Toyoshima J; Kaneko Y; Oda K; Nishimura T Eur J Clin Pharmacol; 2020 Aug; 76(8):1135-1141. PubMed ID: 32472157 [TBL] [Abstract][Full Text] [Related]
10. Rifampin enhances the glucose-lowering effect of metformin and increases OCT1 mRNA levels in healthy participants. Cho SK; Yoon JS; Lee MG; Lee DH; Lim LA; Park K; Park MS; Chung JY Clin Pharmacol Ther; 2011 Mar; 89(3):416-21. PubMed ID: 21270793 [TBL] [Abstract][Full Text] [Related]
11. Organic Cation Transporter 1 Is Responsible for Hepatocellular Uptake of the Tyrosine Kinase Inhibitor Pazopanib. Ellawatty WEA; Masuo Y; Fujita KI; Yamazaki E; Ishida H; Arakawa H; Nakamichi N; Abdelwahed R; Sasaki Y; Kato Y Drug Metab Dispos; 2018 Jan; 46(1):33-40. PubMed ID: 29089306 [TBL] [Abstract][Full Text] [Related]
12. Enhanced and Persistent Inhibition of Organic Cation Transporter 1 Activity by Preincubation of Cyclosporine A. Panfen E; Chen W; Zhang Y; Sinz M; Marathe P; Gan J; Shen H Drug Metab Dispos; 2019 Nov; 47(11):1352-1360. PubMed ID: 31427432 [TBL] [Abstract][Full Text] [Related]
13. Characterization of Contributing Factors to Variability in Morphine Clearance Through PBPK Modeling Implemented With OCT1 Transporter. Emoto C; Fukuda T; Johnson TN; Neuhoff S; Sadhasivam S; Vinks AA CPT Pharmacometrics Syst Pharmacol; 2017 Feb; 6(2):110-119. PubMed ID: 27935268 [TBL] [Abstract][Full Text] [Related]
14. [Pharmacogenomics: inter-ethnic and intra-ethnic differences in pharmacokinetic and pharmacodynamic profiles of clinically relevant drugs]. Ieiri I; Higuchi S Yakugaku Zasshi; 2009 Feb; 129(2):231-5. PubMed ID: 19182452 [TBL] [Abstract][Full Text] [Related]
15. Mechanism of Altered Metformin Distribution in Nonalcoholic Steatohepatitis. Clarke JD; Dzierlenga AL; Nelson NR; Li H; Werts S; Goedken MJ; Cherrington NJ Diabetes; 2015 Sep; 64(9):3305-13. PubMed ID: 26016715 [TBL] [Abstract][Full Text] [Related]
16. The human organic cation transporter OCT1 and its role as a target for drug responses. Brosseau N; Ramotar D Drug Metab Rev; 2019 Nov; 51(4):389-407. PubMed ID: 31564168 [TBL] [Abstract][Full Text] [Related]
17. OCT1 mediates hepatic uptake of sumatriptan and loss-of-function OCT1 polymorphisms affect sumatriptan pharmacokinetics. Matthaei J; Kuron D; Faltraco F; Knoch T; Dos Santos Pereira JN; Abu Abed M; Prukop T; Brockmöller J; Tzvetkov MV Clin Pharmacol Ther; 2016 Jun; 99(6):633-41. PubMed ID: 26659468 [TBL] [Abstract][Full Text] [Related]
18. OCT1 is a high-capacity thiamine transporter that regulates hepatic steatosis and is a target of metformin. Chen L; Shu Y; Liang X; Chen EC; Yee SW; Zur AA; Li S; Xu L; Keshari KR; Lin MJ; Chien HC; Zhang Y; Morrissey KM; Liu J; Ostrem J; Younger NS; Kurhanewicz J; Shokat KM; Ashrafi K; Giacomini KM Proc Natl Acad Sci U S A; 2014 Jul; 111(27):9983-8. PubMed ID: 24961373 [TBL] [Abstract][Full Text] [Related]
19. Hepatic Transporter Alterations by Nuclear Receptor Agonist T0901317 in Sandwich-Cultured Human Hepatocytes: Proteomic Analysis and PBPK Modeling to Evaluate Drug-Drug Interaction Risk. Ito K; Sjöstedt N; Malinen MM; Guo C; Brouwer KLR J Pharmacol Exp Ther; 2020 May; 373(2):261-268. PubMed ID: 32127372 [TBL] [Abstract][Full Text] [Related]
20. Moxifloxacin Is a Potent In Vitro Inhibitor of OCT- and MATE-Mediated Transport of Metformin and Ethambutol. Te Brake LH; van den Heuvel JJ; Buaben AO; van Crevel R; Bilos A; Russel FG; Aarnoutse RE; Koenderink JB Antimicrob Agents Chemother; 2016 Dec; 60(12):7105-7114. PubMed ID: 27645247 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]